Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 1/2018

01-01-2018 | Commentary

An optimal design for the study of palliative sedation—making somewhat better pictures

Authors: Hong Yup Ahn, So Jung Park, Hee Kyung Ahn, In Cheol Hwang

Published in: Supportive Care in Cancer | Issue 1/2018

Login to get access

Excerpt

Palliative sedation refers to the use of sedatives to reduce the consciousness level of patients with the aim of relieving symptoms refractory to any other means of treatment [1]. Among the forms of palliative sedation, continuous deep sedation (CDS) is at the top of a debate concerning the possibility that the greatest effect of palliative sedation is the shortening of life [2]. CDS can trigger lethal pathophysiological cascades related to the pharmacological effects of high-dose sedatives on the respiratory and circulation system [3]. The clinical evidence currently available may set families and palliative care providers free of the guilty feelings associated with hastening a patient’s death [4]. In both ethics and practice, the clarification of whether a forced loss of consciousness curtails a patient’s survival is still of great value. …
Literature
1.
Cherny NI, Radbruch L, Board of the European Association for Palliative C (2009) European Association for Palliative Care (EAPC) recommended framework for the use of sedation in palliative care. Palliat Med 23:581–593CrossRef
2.
Materstvedt LJ, Bosshard G (2009) Deep and continuous palliative sedation (terminal sedation): clinical-ethical and philosophical aspects. Lancet Oncol 10:622–627CrossRef
3.
Rady MY, Verheijde JL (2010) Continuous deep sedation until death: palliation or physician-assisted death? Am J Hosp Palliat Care 27:205–214CrossRef
4.
Papavasiliou EE, Payne S, Brearley S, Euroimpact (2014) Current debates on end-of-life sedation: an international expert elicitation study. Support Care Cancer 22:2141–2149CrossRef
5.
Kitsios GD, Dahabreh IJ, Callahan S, Paulus JK, Campagna AC, Dargin JM (2015) Can we trust observational studies using propensity scores in the critical care literature? A systematic comparison with randomized clinical trials. Crit Care Med 43:1870–1879CrossRef
6.
Maltoni M, Scarpi E, Rosati M et al (2012) Palliative sedation in end-of-life care and survival: a systematic review. J Clin Oncol 30:1378–1383CrossRef
7.
Maeda I, Morita T, Yamaguchi T et al (2016) Effect of continuous deep sedation on survival in patients with advanced cancer (J-Proval): a propensity score-weighted analysis of a prospective cohort study. Lancet Oncol 17:115–122CrossRef
8.
Caraceni A (2016) Palliative sedation: more data and fewer opinions. Lancet Oncol 17:15–17CrossRef
9.
Morita T, Imai K, Yokomichi N, Mori M, Kizawa Y, Tsuneto S (2017) Continuous deep sedation: a proposal for performing more rigorous empirical research. J Pain Symptom Manag 53:146–152CrossRef
10.
Anquinet L, Raus K, Sterckx S, Smets T, Deliens L, Rietjens JA (2013) Similarities and differences between continuous sedation until death and euthanasia—professional caregivers’ attitudes and experiences: a focus group study. Palliat Med 27:553–561CrossRef
Metadata
Title
An optimal design for the study of palliative sedation—making somewhat better pictures
Authors
Hong Yup Ahn
So Jung Park
Hee Kyung Ahn
In Cheol Hwang
Publication date
01-01-2018
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 1/2018
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-017-3925-z

Other articles of this Issue 1/2018

Supportive Care in Cancer 1/2018 Go to the issue

Original Article

Expert agreed standards for the selection and development of cancer support group leaders: an online reactive Delphi study

Original Article

Totally implantable venous access ports: a prospective long-term study of early and late complications in adult patients with cancer

Original Article

Perceived barriers and preferred components for physical activity interventions in African-American survivors of breast or endometrial cancer with type 2 diabetes: the S.U.C.C.E.S.S. framework

Original Article

A Delphi study to develop indicators of cancer patient experience for quality improvement

Review Article

Patient-reported outcome use in oncology: a systematic review of the impact on patient-clinician communication

Original Article

The value of physical performance measurements alongside assessment of sarcopenia in predicting receipt and completion of planned treatment in non-small cell lung cancer: an observational exploratory study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits